EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Multizentrische StudieOpen Access · CC BY 4.0

Efficacy, safety, and tolerability of adjunctive brivaracetam in adult Asian patients with uncontrolled focal‐onset seizures: A phase III randomized, double‐blind, placebo‐controlled trial

Yushi Inoue iD, Somsak Tiamkao, Dong Zhou iD, Leonor Cabral-Lim, Kheng Seang Lim iD, Shih-Hui Lim iD, Jing-Jane Tsai, Brian Moseley iD, Lin Wang iD, Weiwei Sun, Yoshinobu Hayakawa, Hiroshi Sasamoto und 3 weitere

Epilepsia Open · 2024

DOI: 10.1002/epi4.12929 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Epilepsia Open, 2024. Verfasst von Yushi Inoue und 14 weiteren Autor:innen. Beteiligte Einrichtung: NHO Shizuoka Institute of Epilepsy and Neurological Disorders, Shizuoka, Japan. Hauptthemen laut MEDLINE: Anticonvulsants, Pyrrolidinones. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: UCB Pharma.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Evaluate efficacy, safety, and tolerability of adjunctive brivaracetam (BRV) in adult Asian patients with focal‐onset seizures (FOS).

Methods

Phase III, randomized, double‐blind, placebo‐controlled study (EP0083; NCT03083665) evaluating BRV 50 mg/day and 200 mg/day in patients (≥16–80 years) with FOS with/without secondary generalization (focal to bilateral tonic–clonic seizures) despite current treatment with 1 or 2 concomitant antiseizure medications. Following an 8‐week baseline, patients were randomized 1:1:1 to placebo, BRV 50 mg/day, or BRV 200 mg/day, and entered a 12‐week treatment period. Efficacy outcomes: percent reduction over placebo in 28‐day FOS frequency (primary); 50% responder rate in FOS frequency; median percent reduction in FOS frequency from baseline; seizure freedom during treatment period (secondary). Primary safety endpoints: incidences of treatment‐emergent adverse events (TEAEs); TEAEs leading to discontinuation; serious TEAEs.

Results

In this study, 448/449 randomized patients (mean age, 34.5 years; 53.8% female) received ≥1 dose of study medication (placebo/BRV 50 mg/BRV 200 mg/day: n = 149/151/148). Percent reduction over placebo in 28‐day adjusted FOS frequency was 24.5% ( p = 0.0005) and 33.4% ( p < 0.0001) with BRV 50 mg/day and 200 mg/day, respectively, 50% responder rate was 19.0%, 41.1%, and 49.3% with placebo, BRV 50 mg/day, and BRV 200 mg/day, respectively ( p < 0.0001 for both BRV groups vs. placebo). Median percent reduction in FOS frequency from baseline was 21.3%/38.9%/46.7% in patients on placebo/BRV 50 mg/BRV 200 mg/day, respectively. Overall, 0, 7 (4.6%), and 10 (6.8%) patients were classified as seizure‐free during the treatment period on placebo, BRV 50 mg/day, and BRV 200 mg/day, respectively ( p = 0.0146/ p = 0.0017 for BRV 50 mg/200 mg/day vs. placebo, respectively). TEAE incidences were similar between patients on placebo (58.4%) and all patients receiving BRV (58.5%); TEAE incidences for BRV 50 mg/day and BRV 200 mg/day were 57.0% and 60.1%, respectively. Overall, 0.7% of patients on placebo and 2.0% of all patients on BRV reported serious TEAEs (incidences for BRV 50 mg/day and BRV 200 mg/day were 1.3% and 2.7%, respectively), 20.1% of patients on placebo and 33.1% of all patients on BRV reported drug‐related TEAEs (incidences for BRV 50 mg/day and BRV 200 mg/day were 26.5% and 39.9%, respectively), and 4.7% of patients on placebo and 3.0% of all patients on BRV discontinued due to TEAEs (discontinuation incidences for BRV 50 mg/day and BRV 200 mg/day were 2.6% and 3.4%, respectively). Significance Adjunctive BRV was efficacious and well tolerated in adult Asian patients with FOS. Efficacy and safety profiles were consistent with BRV studies in predominantly non‐Asian populations. Plain Language Summary Brivaracetam is used to treat partial or focal seizures in people with epilepsy. Most studies with brivaracetam tablets have involved people from non‐Asian racial backgrounds. In this study, 449 Asian adults with epilepsy took part. One third took 50 mg of brivaracetam, one third took 200 mg of brivaracetam, and one third took a placebo each day for 12 weeks. On average, those who took brivaracetam had fewer seizures than those given the placebo. Most of the side effects were mild and the number and type of side effects seen were as expected for this medication.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AnticonvulsantsPyrrolidinonesHumansDouble-Blind MethodFemaleMaleAdultMiddle AgedYoung AdultAgedTreatment OutcomeDrug Therapy, CombinationSeizuresAdolescentEpilepsies, PartialAsian PeopleAged, 80 and over

Stichwörter der Autor:innen

Asianantiseizure medicationclinical trialconcomitant medicationfocal‐onset epilepsy

Substanzen

brivaracetamAnticonvulsantsPyrrolidinones

Autor:innen und Institutionen

  • NHO Shizuoka Institute of Epilepsy and Neurological Disorders, Shizuoka, Japan.
  • Integrated Epilepsy Research Group, Khon Kaen University, Srinagarind Hospital, Khon Kaen, Thailand.
  • West China Hospital of Sichuan University, Chengdu, Sichuan, China.
  • Department of Neurosciences, College of Medicine, Philippine General Hospital, University of the Philippines Manila, The Health Sciences Center, Manila, Philippines.
  • Division of Neurology, Department of Medicine, Faculty of Medicine, Universiti Malaya, Kuala Lumpur, Malaysia.
  • Singapore General Hospital, Singapore City, Singapore.

ORCID-Profile: Yushi Inoue, Dong Zhou, Kheng Seang Lim, Shih-Hui Lim, Brian Moseley, Lin Wang

Förderung

  • UCB Pharma

Zitieren

APA

Inoue, Y., Tiamkao, S., Zhou, D., Cabral-Lim, L., Lim, K. S., Lim, S. H., Tsai, J. J., Moseley, B., Wang, L., Sun, W., Hayakawa, Y., Sasamoto, H., Sano, T., McClung, C., & Bass, A. (2024). Efficacy, safety, and tolerability of adjunctive brivaracetam in adult Asian patients with uncontrolled focal‐onset seizures: A phase III randomized, double‐blind, placebo‐controlled trial. Epilepsia Open. https://doi.org/10.1002/epi4.12929

Vancouver

Inoue Y, Tiamkao S, Zhou D, Cabral-Lim L, Lim KS, Lim SH, et al. Efficacy, safety, and tolerability of adjunctive brivaracetam in adult Asian patients with uncontrolled focal‐onset seizures: A phase III randomized, double‐blind, placebo‐controlled trial. Epilepsia Open. 2024. doi:10.1002/epi4.12929

BibTeX
@article{Inoue2024,
  author = {Inoue, Yushi and Tiamkao, Somsak and Zhou, Dong and Cabral-Lim, Leonor and Lim, Kheng Seang and Lim, Shih-Hui and Tsai, Jing-Jane and Moseley, Brian and Wang, Lin and Sun, Weiwei and Hayakawa, Yoshinobu and Sasamoto, Hiroshi and Sano, Tomonobu and McClung, Carrie and Bass, Almasa},
  title = {Efficacy, safety, and tolerability of adjunctive brivaracetam in adult Asian patients with uncontrolled focal‐onset seizures: A phase III randomized, double‐blind, placebo‐controlled trial},
  journal = {Epilepsia Open},
  year = {2024},
  doi = {10.1002/epi4.12929}
}
Kostenlos starten →